Key result
Among patients admitted with acute ischaemic stroke, 15% were already taking clopidogrel and 3% were on dual antiplatelets, suggesting a potential need for clopidogrel resistance testing.
Why the study?
Guidelines recommend considering clopidogrel resistance in recurrent stroke, prompting the authors to determine the incidence of strokes in patients taking clopidogrel.
Population
326 patients admitted to a tertiary NHS hospital with acute ischaemic stroke confirmed on CT/MRI
Comparison
Patients taking clopidogrel vs dual antiplatelets or other treatments
Design
Retrospective observational study
Authors
Loading...
May warrant antiplatelet review after breakthrough stroke; leaves open optimal regimen given low-certainty evidence against clopidogrel benefit.
Observational (n=326)
No
A notable proportion of patients presenting with acute ischaemic stroke are already on clopidogrel, highlighting the potential need for clopidogrel resistance testing to individualize treatment.
Rowland et al. (2026) conducted an observational in Acute ischaemic stroke (n=326). Clopidogrel was evaluated on Incidence of strokes in patients on clopidogrel. Among patients admitted with acute ischaemic stroke, 15% were already taking clopidogrel and 3% were on dual antiplatelets, suggesting a potential need for clopidogrel resistance testing.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: